BOSTON, February 28, 2022 — Dewpoint Therapeutics, the biomolecular condensates company, today announced the appointment of Aravind Subramanian, Ph.D., as Head of […]

BOSTON , February 3, 2022 – Dewpoint Therapeutics Inc., the biomolecular condensates company, today announced the completion of a $150 million Series C financing.

BOSTON, September 28, 2021— Dewpoint Therapeutics, the biomolecular condensates company, today announced the appointment of Lori Escobedo as Chief People Officer.

Dewpoint congratulates our scientific founder, Tony Hyman, for his election to the German Academy of Sciences Leopoldina. This prestigious award […]

BOSTON, June 16, 2021 — Dewpoint Therapeutics, the biomolecular condensates company, today announced the appointment of Michael Wagner, Ph.D., as Senior […]

BOSTON, April 21, 2021 — Dewpoint Therapeutics, the biomolecular condensates company, today announced the appointment of Isaac Klein, M.D., Ph.D., as Chief […]

BOSTON, March 9, 2021 – Volastra Therapeutics and Dewpoint Therapeutics today announced a research and development partnership to discover novel modulators of biomolecular condensates […]

BOSTON, February 16, 2021 – Dewpoint Therapeutics, the biomolecular condensates company, today announced that it has appointed Regina Barzilay, Ph.D., to its […]

BOSTON, February 11, 2021 — Dewpoint Therapeutics, the biomolecular condensates company, today announced it has appointed Joel Sendek as Chief Financial Officer […]

A Nature review of condensate focused start-ups has described Dewpoint as the “field’s frontrunner’. The article has profiled three condensate […]

In June 2024, Lis Leiderman, M.D., MBA joined Dewpoint’s Executive Leadership Team as Chief Financial and Corporate Development Officer. With […]

At Dewpoint, we are working to unlock the full potential of condensate science to discover and develop life-changing treatments for […]

At Dewpoint we are embracing all forms of science from biology, chemistry and physics to data science and artificial intelligence […]

“I believe we are on our way towards a MYC c-mod, says Bede Portz, Dewpoint’s ovarian cancer program lead. Our […]